Alexander Deneka, Md, Phd Email & Phone Number

Los Angeles, CA, US

Los Angeles, California, United States

Developing pipelines for precision medicine oncology solutions. R&D lead, scientific liaison.Feasibility and risk assessments.

• Analyzing Big Data from clinical, transcriptome, and genomic datasets to discover new approaches to treat Fanconi Anemia-related diseases and characterize signaling aberrations between pancreatic cancer cells and.
• Discovered the role of PKD1 alterations in the initiation and progression of colorectal cancer and proposed a new model in which this gene plays a central role in controlling colon inflammation, cancer risk, and.
• Applying research expertise to manage the completion of research projects, demonstrating effective remote collaboration and communication skills to maintain productivity and facilitate project advancement.

Philadelphia, Pennsylvania, United States

• Identified the novel role of NEDD9 scaffolding protein in the regulation of glycolysis in non-small cell lung cancer. Conducted immunohistochemical, proteomic, and molecular analyses (multiplex assays (Luminex), IP-MS.
• Identified Musashi-2 protein as a potential biomarker and targeted therapy enhancer for EGFR-mutant non-small cell lung cancer, and biomarker of response in colon cancer. Utilized extensive proteomics research, in vivo.
• Developed project strategy and presented the data at scientific meetings.
• Demonstrated high productivity with >10 publications (5 first-author papers) in high-impact journals over 3 years.

Philadelphia, Pennsylvania, United States

• Evaluated targeted cancer therapies for autosomal dominant polycystic kidney disease to offer the opportunity to repurpose drugs initially developed for cancer into the setting of PKD; a disease lacking effective.
• Defined novel role of NEDD9 scaffolding protein in the regulation of autophagy and Inflammation. Generated and extensively characterized a novel transgenic lung cancer murine model. Utilized small imaging techniques.
• Identified off-target effects of targeted drugs in polycystic kidney diseases and kidney cancer via regulation of ciliation. Utilized in vivo xenograft models of kidney cancer, immunofluorescence microscopy (IF).
• Mentored junior trainees, PhD students, and rotating lab students. Demonstrated high productivity in research: published 7 papers in 3 years in high-impact journals

Philadelphia, Pennsylvania, United States

• Drove successful completion and close-out of 3 trials in 6 months by increasing the studies’ accrual number; achieved this by establishing effective communication with healthcare providers and providing them with.
• Oversaw a portfolio of 7 Phase I Oncology trials acting as a critical facilitator for a multidisciplinary team.
• Collaborated with patients and principal investigators, meticulously completing/verifying eligibility checklists to ensure trial suitability, participated in study review processes.
• Conducted thorough reviews of case report forms (CRFs) and generated data reports to guarantee completeness and accuracy of clinical data collection and presentation.
• Ensured full compliance with federal, institutional, and state regulations throughout study execution and close-out phases.
• Additionally, managed data and regulatory oversight, ensuring seamless coordination.

New Haven, Connecticut, United States

• Conducted preclinical testing of novel treatments targeting cell cycle checkpoints in HPV-negative head and neck cancers. Demonstrated preclinical efficacy of cell cycle checkpoint-targeting compounds adavosertib and.
• Characterized patterns of mutations in major oncosuppressors (TP53 and CDKN2A) in HPV-negative head and neck cancers to identify potential biomarkers of disease. Analyzed big data from clinical, transcriptome, and.

Kazan, Tatarstan, Russia

• Secured funding (three grants were funded) and led research investigating novel prediction markers and treatment approaches for lung cancer. Conducted study design and execution, strategy development, budgeting, staff.
• Crresponding author on 3 published articles, highlighting the role of NEDD9 protein as biomarker of disease progression and critical regulator of DNA damage response in non-small cell lung cancer.
• Under my mentorship, two thesis projects (PhD and Masters in Biochemistry) were successfully defended.

Philadelphia, Pennsylvania, United States

• Thesis work focused on studying cell signaling and the evaluation of novel therapies for lung cancer. Gained extensive experience in studying claudins, epithelial-mesenchymal transition, and tumor invasion, utilizing.
• Investigated the activation of oncogenic signaling pathways in the context of polycystic kidney disease and their failure to generate tumors. Supported primary research study with a comprehensive literature review and.
• Secured a highly competitive Fellowship Award to continue translational research in cancer biology at Fox Chase Cancer Center.

Lexington, Massachusetts, United States

• Tested a new HSP90 drug conjugate for small cell lung cancer treatment. Established pre-clinical efficacy, PK/PD, and MOA, supporting drug transition to clinical trials. Compound is currently in Phase 1/2 trial.
• Xenograft studies, injections, tissue collection and processing. Cell-based assays development – flow cytometry, proliferation & cytotoxicity assays, ELISA.

Moscow, Russia

• Led department at Astellas Pharma Europe BV to improve the regional distribution of the company’s portfolio of anti-bacterial agents: amoxicillin (flemoxin solutab), amoxiclav (flemoclav solutab), josamycin (wilprafen).
• Exceeded annual territory goals in one year by establishing professional relationships with KOLs and providing them with the necessary scientific background to ensure more efficient provision of quality patient care.
• Served as the main point of contact for presentations (local conferences and advisory boards), regulatory compliance (assisting in clinical guidelines design), and maintenance of relationships with KOLs: HCPs (10+.
• Participated in territory plan development, reviewed and adapted scientific trainings to provide mentoring for peers in commercial department, collaborated with cross-functional partners in R&D.

Moscow, Russia

• Provided coverage for the OR and ER during 10-hour shifts, working under the supervision of attending physicians.
• Utilized clinical skills in surgical care for both planned and emergency surgical cases.
• Demonstrated proficiency in post-operative management and ICU coverage. Delivered intensive care for critically ill patients.
• Exhibited strong interpersonal communication skills and teamwork in a fast-paced medical environment.

Doctor Of Philosophy - Phd, Biochemistry, Biomedical Sciences

Adjunct program with Kazan Federal University

Doctor Of Medicine (M.D.), Medicine

Activities and Societies: Chair, Moscow State University Faculty of Basic Medicine Student Scientific Society, 10/2009 – 05/2010Graduated.

Doctor Of Philosophy (Ph.D.), Biochemistry, Biomedical Sciences